PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...

Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model. Background: Chemokine receptors have been shown to regulate the progression ...

Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...